Insider Selling: Kiniksa Pharmaceuticals, Ltd. (NASDAQ:KNSA) CFO Sells 18,299 Shares of Stock

Kiniksa Pharmaceuticals, Ltd. (NASDAQ:KNSA - Get Free Report) CFO Mark Ragosa sold 18,299 shares of Kiniksa Pharmaceuticals stock in a transaction on Tuesday, June 3rd. The shares were sold at an average price of $28.80, for a total transaction of $527,011.20. Following the completion of the transaction, the chief financial officer now directly owns 27,009 shares in the company, valued at $777,859.20. The trade was a 40.39% decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available at this link.

Mark Ragosa also recently made the following trade(s):

• On Wednesday, April 30th, Mark Ragosa sold 21,254 shares of Kiniksa Pharmaceuticals stock. The stock was sold at an average price of $26.95, for a total value of $572,795.30.
• On Wednesday, March 19th, Mark Ragosa sold 8,879 shares of Kiniksa Pharmaceuticals stock. The stock was sold at an average price of $23.10, for a total value of $205,104.90.
• On Monday, March 17th, Mark Ragosa sold 11,464 shares of Kiniksa Pharmaceuticals stock. The stock was sold at an average price of $23.10, for a total value of $264,818.40.
• On Wednesday, March 12th, Mark Ragosa sold 36,372 shares of Kiniksa Pharmaceuticals stock. The stock was sold at an average price of $22.25, for a total value of $809,277.00.

Kiniksa Pharmaceuticals Stock Performance

Shares of KNSA stock traded up $0.40 during trading hours on Friday, hitting $29.92. The company had a trading volume of 516,835 shares, compared to its average volume of 500,410. The firm's fifty day moving average is $24.10 and its 200 day moving average is $21.84. The firm has a market capitalization of $2.18 billion, a price-to-earnings ratio of -213.73 and a beta of 0.06. Kiniksa Pharmaceuticals, Ltd. has a 12 month low of $17.38 and a 12 month high of $29.98.

Kiniksa Pharmaceuticals (NASDAQ:KNSA - Get Free Report) last released its quarterly earnings results on Tuesday, April 29th. The company reported $0.11 EPS for the quarter, beating analysts' consensus estimates of $0.02 by $0.09. Kiniksa Pharmaceuticals had a negative net margin of 2.36% and a negative return on equity of 7.31%. The firm had revenue of $137.79 million for the quarter, compared to analyst estimates of $128.35 million. During the same period in the previous year, the business earned ($0.25) earnings per share. The company's revenue for the quarter was up 72.5% compared to the same quarter last year. On average, sell-side analysts expect that Kiniksa Pharmaceuticals, Ltd. will post -0.55 EPS for the current fiscal year.

Institutional Inflows and Outflows

Institutional investors and hedge funds have recently added to or reduced their stakes in the stock. Rhumbline Advisers boosted its position in Kiniksa Pharmaceuticals by 6.4% in the 1st quarter. Rhumbline Advisers now owns 62,700 shares of the company's stock valued at $1,393,000 after buying an additional 3,745 shares during the last quarter. Strs Ohio bought a new stake in shares of Kiniksa Pharmaceuticals during the first quarter worth approximately $595,000. Acadian Asset Management LLC grew its holdings in Kiniksa Pharmaceuticals by 170.3% during the 1st quarter. Acadian Asset Management LLC now owns 1,034,321 shares of the company's stock worth $22,961,000 after acquiring an additional 651,700 shares during the period. Fred Alger Management LLC acquired a new position in shares of Kiniksa Pharmaceuticals in the 1st quarter valued at $485,000. Finally, Millennium Management LLC lifted its stake in shares of Kiniksa Pharmaceuticals by 8.7% in the 1st quarter. Millennium Management LLC now owns 847,124 shares of the company's stock valued at $18,815,000 after purchasing an additional 67,452 shares during the period. Institutional investors and hedge funds own 53.95% of the company's stock.

Analysts Set New Price Targets

KNSA has been the subject of a number of research reports. Citigroup initiated coverage on Kiniksa Pharmaceuticals in a report on Thursday, March 13th. They set a "buy" rating and a $40.00 target price for the company. Jefferies Financial Group raised their price target on Kiniksa Pharmaceuticals from $40.00 to $45.00 and gave the stock a "buy" rating in a report on Tuesday, April 29th. Finally, Wedbush reaffirmed an "outperform" rating and issued a $34.00 price objective on shares of Kiniksa Pharmaceuticals in a report on Wednesday, April 16th. Five research analysts have rated the stock with a buy rating, According to data from MarketBeat, the stock has an average rating of "Buy" and an average price target of $38.80.

Kiniksa Pharmaceuticals Company Profile

Kiniksa Pharmaceuticals, Ltd., a biopharmaceutical company, focuses on discovering, acquiring, developing, and commercializing therapeutic medicines for patients suffering from debilitating diseases with significant unmet medical needs worldwide. Its product candidates include ARCALYST, an interleukin-1alpha and interleukin-1beta, for the treatment of recurrent pericarditis, which is an inflammatory cardiovascular disease; Mavrilimumab, a monoclonal antibody inhibitor that completed Phase II clinical trials for the treatment of giant cell arteritis; Vixarelimab, a monoclonal antibody, that is in Phase 2b clinical trial for the treatment of prurigo nodularis, a chronic inflammatory skin condition; and KPL-404, a monoclonal antibody inhibitor of the CD40- CD154 interaction, a T-cell co-stimulatory signal critical for B-cell maturation, immunoglobulin class switching, and type 1 immune response.